SSKN · As filed with the SEC
STRATA Skin Sciences balance sheet, by quarter
The statement as STRATA Skin Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD thousands
| USD thousands | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 7,912 | 7,076 | 5,966 | 6,512 | 7,261 | 7,062 | 5,483 | 5,237 |
| Restricted cash | 0 | 0 | 0 | 1,334 | 1,334 | 1,334 | 1,334 | 1,334 |
| Accounts receivable, net of allowance for credit losses of $551 and $433 at December 31, 2025 and 2024, respectively | 4,121 | 3,504 | 4,022 | 5,007 | 5,253 | 4,443 | 3,979 | 3,630 |
| Inventories | 2,814 | 3,058 | 3,236 | 2,659 | 2,246 | 2,744 | 2,692 | 2,695 |
| Prepaid expenses and other current assets | 753 | 634 | 550 | 364 | 501 | 297 | 337 | 343 |
| Total current assets | 15,600 | 14,272 | 13,774 | 15,876 | 16,595 | 15,880 | 13,825 | 13,239 |
| Property and equipment, net | 8,964 | 9,557 | 8,604 | 9,462 | 10,061 | 10,387 | 11,149 | 11,726 |
| Operating lease right-of-use assets | 920 | 1,005 | 1,092 | 1,179 | 1,264 | 1,348 | 1,429 | 1,508 |
| Intangible assets, net | 3,377 | 4,223 | 4,363 | 4,856 | 5,348 | 5,840 | 6,334 | 6,825 |
| Goodwill | 1,429 | 1,429 | 2,658 | 2,658 | 2,658 | 6,519 | 6,519 | 6,519 |
| Other assets | 231 | 231 | 231 | 231 | 231 | 231 | 325 | 231 |
| Total assets | 30,521 | 30,717 | 30,722 | 34,262 | 36,157 | 40,205 | 39,581 | 40,048 |
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Current portion of long-term debt | 15,349 | 1,875 | — | — | — | — | — | — |
| Accounts payable | 2,758 | 2,955 | 2,945 | 2,816 | 2,433 | 1,749 | 2,886 | 3,592 |
| Accrued expenses and other current liabilities | 6,155 | 6,210 | 7,401 | 8,779 | 8,593 | 8,524 | 6,608 | 6,269 |
| Deferred revenues | 2,248 | 2,551 | 2,372 | 2,204 | 2,241 | 2,421 | 2,261 | 2,366 |
| Current portion of operating lease liabilities | 231 | 266 | 303 | 331 | 328 | 322 | 313 | 300 |
| Current portion of contingent consideration | 0 | 1,176 | 983 | 1,009 | 1,030 | 1,030 | 65 | 61 |
| Total current liabilities | 26,741 | 15,033 | 14,004 | 15,139 | 14,625 | 14,046 | 12,133 | 12,588 |
| Long-term debt, net | 0 | 13,435 | 15,270 | 15,231 | 15,192 | 15,153 | 15,114 | 15,075 |
| Deferred revenues and other liabilities | 184 | 199 | 264 | 292 | 353 | 379 | 473 | 480 |
| Deferred tax liability | — | — | — | — | 0 | 186,000 | 186,000 | 186,000 |
| Operating lease liabilities, net of current portion | 688 | 736 | 780 | 835 | 919 | 1,002 | 1,083 | 1,166 |
| Contingent consideration, net of current portion | 0 | 0 | 96 | 96 | 96 | 96 | 1,096 | 1,121 |
| Total liabilities | 27,613 | 29,403 | 30,414 | 31,593 | 31,185 | 30,862 | 30,085 | 30,616 |
| Stockholders’ equity: | ||||||||
| Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common stock, $0.001 par value; 150,000,000 shares authorized; 5,888,199 and 4,171,161 shares issued and outstanding at December 31, 2025 and 2024, respectively | 6 | 5 | 4 | 4 | 4 | 4 | 4 | 35 |
| Additional paid-in capital | 257,307 | 255,772 | 253,369 | 253,241 | 253,112 | 252,986 | 251,017 | 250,823 |
| Accumulated deficit | (254,405) | (254,463) | (253,065) | (250,576) | (248,144) | (243,647) | (241,525) | (241,426) |
| Total stockholders’ equity | 2,908 | 1,314 | 308 | 2,669 | 4,972 | 9,343 | 9,496 | 9,432 |
| Total liabilities and stockholders’ equity | 30,521 | 30,717 | 30,722 | 34,262 | 36,157 | 40,205 | 39,581 | 40,048 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.
Data on this page was fetched . The filing on SEC.gov is the record.